Novel targets for valproic acid: Up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells

Journal of Neurochemistry

Volumn 95, Issue 5, 2005, Pages 1227-1236

  Castro, Lyda M Rincón ^a   Gallant, Michel ^a   Niles, Lennard P ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Brain derived neurotrophic factor; Glial cell line derived neurotrophic factor; Histone acetylation; Melatonin MT1 and MT2 receptors; Mitogen activated protein kinase extracellular signal regulated kinase pathway; Neuroprotection

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HISTONE DEACETYLASE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NEUROTROPHIC FACTOR; PINEAL BODY HORMONE; VALPROIC ACID;

ANIMAL CELL; ARTICLE; CENTRAL NERVOUS SYSTEM; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; GABAERGIC SYSTEM; GENETIC TRANSCRIPTION; GLIOMA CELL; IMMUNOCYTOCHEMISTRY; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; GLIOMA; HISTONE DEACETYLASES; IMMUNOHISTOCHEMISTRY; MICE; NERVE GROWTH FACTORS; RECEPTORS, MELATONIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION; VALPROIC ACID;

ANIMALIA; MAMMALIA;

EID: 28844473025     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2005.03457.x     Document Type: Article

References (37)

1. Airaksinen M. S. and Saarma M. (2002) The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 5, 383-394.
2. Ajamian F., Salminen A. and Reeben M. (2004) Selective regulation of class I and class II histone deacetylases expression by inhibitors of histone deacetylases in cultured mouse neural cells. Neurosci. Lett. 365, 64-68.
3. Armstrong K. J. and Niles L. P. (2002) Induction of GDNF mRNA expression by melatonin in rat C6 glioma cells. Neuroreport 13, 473-475.
4. Asghari V., Wang J. F., Reiach J. S. and Young L. T. (1998) Differential effects of mood stabilizers on Fos/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY5Y cells. Mol. Brain Res. 58, 95-102.
5. Baecker P. A., Lee W. H., Verity A. N., Eglen R. M. and Johnson R. M. (1999) Characterization of a promoter for the human glial cell line derived neurotrophic factor gene. Mol. Brain Res. 69, 209-222.
6. Chen G., Yuan P., Hawver D. B., Potter W. Z. and Manji H. K. (1997) Increase in AP-1 transcription factor DNA binding activity by valproic acid. Neuropsychopharmacology 16, 238-245.
7. Chen G., Zeng W. Z., Yuan P. X., Huang L. D., Jiang Y. M., Zhao Z. H. and Manji H. K. (1999a) The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 72, 879-882.
8. Chen G., Yuan P. X., Jiang Y. M., Huang L. D. and Manji H. K. (1999b) Valproate robustly enhances AP-1 mediated gene expression. Mol. Brain Res. 64, 52-58.
9. Fernandez-Espejo E. (2004) Pathogenesis of Parkinson's disease: prospects of neuroprotective and restorative therapies. Mol. Neurobiol. 29, 15-30.
10. Fukumoto T., Morinobu S., Okamoto Y., Kagaya A. and Yamawaki S. (2001) Chronic lithium treatment increases the expression of brain derived neurotrophic factor in the rat brain. Psychopharmacology 158, 100-106.
11. von Gall C., Stehle J. H. and Weaver D. R. (2002) Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res. 309, 151-162.
12. Hao Y., Creson T., Zhang L., Li P., Du F., Yuan P., Gould T. D., Manji H. K. and Chen G. (2004) Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J. Neurosci. 24, 6590-6599.
13. Jeong M. R., Hashimoto R., Senatorov V. V., Fujimaki K., Ren M., Lee M. S. and Chuang D. M. (2003) Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition. FEBS Lett. 542, 74-78.
14. Mazzucchelli C., Pannacci M., Nonno R., Lucini V., Fraschini F. and Stankov B. M. (1996) The melatonin receptor in the human brain: cloning experiments and distribution studies. Mol. Brain Res. 39, 117-126.
15. Meller R., Babity J. M. and Grahame-Smith D. G. (2002) 5-HT2A receptor activation leads to increased BDNF mRNA expression in C6 glioma cells. Neuromol. Med. 3, 197-205.
16. Milanini J., Vinals F., Pouyssegur J. and Pages G. (1998) p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J. Biol. Chem. 273, 18 165-18 172.
17. Nakayama M., Gahara Y., Kitamura T. and Ohara O. (1994) Distinctive four promoters collectively direct expression of brain-derived neurotrophic factor gene. Mol. Brain Res. 21, 206-218.
18. Niles L. P. (1997) G protein-coupled melatonin receptors, in G Protein Methods and Protocols: Role of G Proteins in Psychiatric and Neurologic Disorders (Mishra R. K., Baker G. B. and Boulton A. A., eds), Neuromethods, Vol. 31, pp. 223-281. Humana. Press Inc., New Jersey.
19. Niles L. P. and Armstrong K. J. (2002) Modulation of GDNF expression by melatonin. 32nd Annual Meeting. Soc. Neurosci. Abstr. no. 691.2.
20. Niles L. P., Smith L. J. and Tenn C. C. (1997) Modulation of c-fos expression in the rat striatum by diazepam. Neurosci. Lett. 236, 5-8.
21. Niles L. P., Wang J., Shen L., Lobb D. K. and Younglai E. V. (1999) Melatonin receptor mRNA expression in human granulosa cells. Mol. Cell. Endocrinol. 156, 107-110.
22. Niles L. P., Armstrong K. J., Rincón Castro L. M., Dao C. V., Sharma R., McMillan C. R., Doering L. C. and Kirkham D. L. (2004) Neural stem cells express melatonin receptors and neurotrophic factors: colocalization of the MT1 receptor with neuronal and glial markers. BMC Neurosci. 5, 41.
23. Perucca E. (2002) Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16, 695-714.
24. Petit L., Lacroix I., de Coppet P., Strosberg A. D. and Jockers R. (1999) Differential signaling of human Mel1a and Mel1b melatonin receptors through the cyclic guanosine 3′-5′-monophosphate pathway. Biochem. Pharmacol. 58, 633-639.
25. Phiel C. J., Zhang F., Huang E. Y., Guenther M. G., Lazar M. A. and Klein P. S. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276, 36 734-36 741.
26. Rincón Castro L. M., Gallant M. J. and Niles L. P. (2003) Induction of melatonin receptor and neurotrophin expression by valproate. 33rd Annual Meeting. Soc. Neurosci. Abstr. no. 896.7.
27. Rivera-Bermudez M. A., Masana M. I., Brown G. M., Earnest D. J. and Dubocovich M. L. (2004) Immortalized cells from the rat suprachiasmatic nucleus express functional melatonin receptors. Brain Res. 1002, 21-27.
28. Rousell J., Haddad E.-B., Lindsay M. A. and Barnes P. J. (1997) Regulation of m2 muscarinic receptor gene expression by platelet-derived growth factor: involvement of extracellular signal-regulated protein kinases in the down-regulation process. Mol. Pharmacol. 52, 966-973.
29. Roy D. and Belsham D. D. (2002) Melatonin receptor activation regulates GnRH gene expression and secretion in GT1-7 GnRH neurons. Signal transduction mechanisms. J. Biol. Chem. 1, 251-258.
30. Song Y., Chan C. W., Brown G. M., Pang S. F. and Silverman M. (1997) Studies of the renal action of melatonin: evidence that the effects are mediated by 37 kDa receptors of the Mel1a subtype localized primarily to the basolateral membrane of the proximal tubule. FASEB J. 11, 93-100.
31. Synowitz M., Ahmann P., Matyash M., Kuhn S. A., Hofmann B., Zimmer C., Kirchhoff F., Kiwit J. C. and Kettenmann H. (2001) GABA(A)-receptor expression in glioma cells is triggered by contact with neuronal cells. Eur. J. Neurosci. 14, 1294-1302.
32. Vanecek J. (1998) Cellular mechanisms of melatonin action. Physiol. Rev. 78, 687-721.
33. A receptor function by Mel1a and Mel1b receptors. Nat. Neurosci. 2, 401-407.
34. Wang F. J., Azzam E. J. and Young L. T. (2003) Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neuroscience 116, 485-489.
35. Witt-Enderby P. A., MacKenzie R. S., McKeon R. M., Carroll E. A., Bordt S. L. and Melan M. A. (2000) Melatonin induction of filamentous structures in non-neuronal cells that is dependent on expression of the human mtl melatonin receptor. Cell Motil. Cytoskeleton 46, 28-42.
36. Wu X., Zhu D., Jiang X., Okagaki P., Mearow K., Zhu G., McCall S., Banaudha K., Lipsky R. H. and Marini A. M. (2004) AMPA protects cultured neurons against glutamate excitotoxicity through a phosphatidylinositol 3-kinase-dependent activation in extracellular signal-regulated kinase to upregulate BDNF gene expression. J. Neurochem. 90, 807-818.
37. Yuan P. X., Huang L. D., Jiang Y. M., Gutkind J. S., Manji H. K. and Chen G. (2001) The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neunte growth. J. Biol. Chem. 276, 31 674-31 683.